Day: April 5, 2021

2. märtsil 2021 alustas OÜ ALARMO KAPITAL („Ülevõtja“) kohustusliku ülevõtmispakkumisega („Pakkumine“) Arco Vara AS („Arco Vara“) aktsiate omandamiseks. Pakkumise tähtaeg saabus 31. märtsil 2021 kell 16.00. Pakkumise raames Ülevõtja poolt pakutud ostuhind oli 1,30 eurot iga Arco Vara aktsia kohta. 5. aprillil 2021. a avalikustas Ülevõtja Nasdaq Tallinna börsil avalikustatud börsiteatega Pakkumise tulemused. Vastavalt nimetatud börsiteatele otsustasid Pakkumise aktseptinud Arco Vara aktsionärid müüa Ülevõtjale Pakkumise raames kokku 1 284 354 Arco Vara aktsiat, mis moodustab ligikaudu 14,2732% kõigist Arco Vara aktsiatest. Koos Pakkumise tulemusel omandatavate Arco Vara aktsiatega saab pärast nimetatud aktsiate Ülevõtjale ülekandmist Ülevõtjale kuuluma kokku 5 948 596 Arco Vara aktsiat, mis moodustab ligikaudu 66,1075% kõigist Arco Vara...

TORONTO, April 05, 2021 (GLOBE NEWSWIRE) — CHAR Technologies Ltd. (“CHAR”) (TSXV: YES) reports that at its Annual and Special Meeting of Shareholders (“Meeting”) held on March 30, 2021, CHAR’s disinterested common shareholders approved the adoption of an omnibus long-term incentive plan (the “Omnibus Plan”) for purposes of attracting, retaining and motivating key individuals. The Omnibus Plan permits such number of options (each, an “Option”) to be granted equal to up to 10% of CHAR’s issued and outstanding common shares from time to time together with 3,530,442 common shares of CHAR available for issuance pursuant to restricted shares, restricted share units, deferred share units and share appreciation rights (being 5% of the total issued and outstanding common shares of CHAR when the Omnibus Plan was approved by CHAR’s board of...

AUSTIN, Texas, April 05, 2021 (GLOBE NEWSWIRE) — Resonant Inc. (NASDAQ: RESN), a provider of radio frequency (RF) filter solutions developed on a robust intellectual property platform, designed to connect People and Things, has signed an extension to its licensing agreement with an existing Tier-1 Chinese foundry partner, providing prepaid royalties for multiple RF filter designs to address the China mobile handset market. The new licensed bands leverage Resonant’s current standard product library, allowing a quick time to market for customers. The agreement carries upfront prepaid royalties, as well as additional per unit royalties, after minimum production volumes are exceeded. “The Chinese mobile handset market continues to grow at a rapid pace, as demonstrated by our Tier-1 foundry partner’s desire to license designs for four...

LAS VEGAS, April 05, 2021 (GLOBE NEWSWIRE) — Marathon Digital Holdings, Inc. (NASDAQ:MARA) (“Marathon” or “Company”), one of the largest enterprise Bitcoin self-mining companies in North America, today published unaudited bitcoin (“BTC”) production and miner installation updates for the first quarter, ended March 31, 2021. Preliminary First Quarter 2021 HighlightsProduced 196 new minted bitcoins in the first quarter of 2021, increasing total bitcoin holdings to 5,134.2 with a fair market value of approximately $301.9 million as of March 31, 2021 At March 31, 2021, cash on hand was approximately $212 million and total liquidity, defined as cash and bitcoin holdings, was approximately $513.9 million Received approximately 10,300 S-19 Pro ASIC miners from Bitmain during the first quarter of 2021 Bitcoin...

TEMPE, Ariz., April 05, 2021 (GLOBE NEWSWIRE) — Wrap Technologies, Inc. (the “Company” or “WRAP”) (Nasdaq: WRAP), a global leader in innovative public safety technologies and services, announced today two new international orders for BolaWrap® products and accessories. WRAP received a new international order for 270 BolaWrap devices and accessories, as the Company builds its global presence to 37 countries. Separately, WRAP also received a reorder for 300 BolaWrap devices plus accessories. “Just as many domestic police departments are recognizing the value of BolaWrap, increasing interest in our products outside the U.S. demonstrates the need for our safety technologies,” said Tom Smith, CEO and President of WRAP. “International business interest and activity continues despite ongoing international travel restrictions due to COVID....

WATERTOWN, Mass., April 05, 2021 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in a fireside chat and one-on-one investor meetings at the virtual 20th Annual Needham Healthcare Conference to be held April 12-15, 2021. Details on the presentation can be found below. Date: Tuesday, April 13Fireside chat time: 3:00 p.m. ETWebcast: Click Here An archived webcast will also be available in the Investors & Media section of the company’s website at www.selectabio.com. About Selecta Biosciences, Inc.Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically...

IRVINE, Calif., April 05, 2021 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the enrollment of the first high-risk pulmonary embolism (“PE”) patient in the FlowTriever for Acute Massive Pulmonary Embolism study (“FLAME”). One in 20 PE diagnoses is categorized as high-risk and these are associated with a mortality rate of up to 40% at 90 days. The first FLAME patient was enrolled at the Penn Presbyterian Hospital & Hospital of the University of Pennsylvania (“HUP”) by co-principal investigators Dr. Sameer J. Khandhar and Dr. Jay S. Giri. “We are pleased to be the first site to enroll a patient in FLAME,” said Dr. Khandhar, Interventional Cardiologist,...

BOSTON and ROCKVILLE, Md., April 05, 2021 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointment of Jessie M. English, Ph.D. to its Board of Directors. Dr. English is a proven biotechnology leader and brings over 20 years of experience in oncology research as well as business and leadership development. “Jessie’s experience in building vibrant, data-driven companies will serve as an important asset to our Board of Directors as we continue to build Sensei Bio’s research capabilities and pipeline. I am excited to welcome her to our Board of Directors at this critical time in Sensei’s development. Her expertise in both oncology drug discovery and business development will...

PEARL RIVER, N.Y., April 05, 2021 (GLOBE NEWSWIRE) — Sterling National Bank, the wholly-owned operating bank subsidiary of Sterling Bancorp (NYSE: STL), today announced a Banking as a Service (BaaS) agreement with Rho Technologies, the fintech company behind Rho Business Banking. Rho Technologies is a digital platform that provides companies with a suite of commercial banking and financial software solutions. Sterling will provide Rho with a holistic package of wholesale banking solutions to support their rapid expansion and accelerate customer growth. This collaboration is a multi-service partnership that combines Sterling’s product, operational and regulatory expertise with Rho’s sophisticated technology and product capabilities. This collaboration marks the latest in a series of strategic partnerships and digital technology investments...

– Data add to growing body of pre-clinical evidence demonstrating that VIR-7831 maintains activity against all known circulating variants of concern – – Plasma from vaccinated individuals and several therapeutic monoclonal antibodies showed a reduction in neutralization potency against the California variant – SAN FRANCISCO, April 05, 2021 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new preclinical research demonstrating the ability of VIR-7831, the company’s investigational SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) monoclonal antibody (mAb), to maintain its neutralizing activity against a mutation in the receptor binding domain (RBD) of SARS-CoV-2, called L452R, which is found in the California variant (B.1.427/B.1.429). Study results also demonstrate that the L452R mutation reduced...